{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:34:00Z","timestamp":1791956040040,"version":"4.3.4"},"reference-count":53,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":796,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p>A growing body of evidence suggests that antidepressant therapies, particularly selective serotonin reuptake inhibitors and venlafaxine, are effective in the management of hot flash symptoms. Several of these agents have the support of the American College of Obstetricians and Gynecologists and the North American Menopause Society. To review the literature on antidepressants for the treatment of hot flashes in women, we searched the PubMed, International Pharmaceutical Abstracts, and MEDLINE databases from inception through May 2009. All publication types that included human participants and that were published in English were eligible for review. These articles, relevant abstracts, and additional references were used to collect pertinent data. Although initial small pilot trials were conducted solely in breast cancer survivors, additional studies have been conducted both in breast cancer survivors and in relatively healthy menopausal women. Data on the benefits with many of these agents are conflicting. Venlafaxine and paroxetine have been studied more extensively than any of the other antidepressants and are more consistent in effectively reducing the frequency and severity of hot flashes, based on these study results. Desvenlafaxine, sertraline, fluoxetine, and citalopram should be considered second\u2010 or third\u2010line options if patients fail therapy with or cannot tolerate venlafaxine or paroxetine, based on the current published data. Duloxetine, escitalopram, fluvoxamine, and mirtazapine should be reserved as last\u2010line therapy until more rigorous studies are conducted assessing their use in the management of hot flashes.<\/jats:p>","DOI":"10.1592\/phco.29.11.1357","type":"journal-article","created":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T14:24:23Z","timestamp":1256567063000},"page":"1357-1374","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Use of Antidepressants for Management of Hot Flashes"],"prefix":"10.1002","volume":"29","author":[{"given":"Dana G.","family":"Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi W.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_1_3_2","first-page":"S106","article-title":"Vasomotor symptoms","volume":"4","author":"American College of Obstetricians and Gynecologists.","year":"2004","journal-title":"Obstet Gynecol"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.GME.0000108177.85442.71"},{"key":"e_1_2_1_5_2","first-page":"50","article-title":"Pilot evaluation of mirtazapine for the treatment of hot flashes","volume":"2","author":"Perez D","year":"2004","journal-title":"J Support Oncol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(00)00151-1"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1985.tb03243.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(91)90282-4"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1578"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(98)00025-5"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(92)90116-L"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.1.79.34812"},{"key":"e_1_2_1_13_2","volume-title":"Effexor XR (venlafaxine) package insert","author":"Wyeth Pharmaceuticals Inc.","year":"2008"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2377"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03403-6"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1188\/02.ONF.33-40"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-1-124"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl478"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7324"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000147840.06947.46"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/da.20085"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000297371.89129.b3"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0619"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00379-2"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.21.2827"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008382706068"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.081"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.10.007"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg108"},{"key":"e_1_2_1_30_2","first-page":"373","article-title":"Hot flashes in breast cancer survivors: effectiveness of low dosage fluoxetine\u2014a pilot study","volume":"24","author":"Mariani K","year":"2005","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02849914"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200512010-00006"},{"key":"e_1_2_1_33_2","volume-title":"Prozac (fluoxetine) package insert","author":"Eli Lily and Company.","year":"2008"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1075-122X.2006.00218.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000196595.82452.ca"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000258278.73505.fa"},{"key":"e_1_2_1_37_2","first-page":"47","article-title":"Pilot evaluation of citalopram for the relief of hot flashes","volume":"1","author":"Barton DL","year":"2003","journal-title":"J Support Oncol"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2005.8.924"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000243571.55699.4a"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000240633.46300.fa"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/1751-0759-1-1"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2005.00254.x"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(00)00152-3"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.2007.00470.x"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67215-7"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.5390"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000222383.43913.ed"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02712-6"},{"key":"e_1_2_1_49_2","first-page":"CD001395","article-title":"Phytoestrogens for vasomotor menopausal symptoms","author":"Lethaby AE","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200209000-00005"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200007040-00005"},{"key":"e_1_2_1_52_2","first-page":"CD002978","article-title":"Oral oestrogen and combined oestrogen\/progesten therapy versus placebo for hot flushes","author":"MacLennan AH","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_53_2","unstructured":"Natural Medicines Comprehensive Database.Soy. Available fromhttp:www.naturaldatabase.com. Accessed June 14 2009."},{"key":"e_1_2_1_54_2","unstructured":"Natural Medicines Comprehensive Database. Black cohosh. Available fromhttp:www.naturaldatabase.com. Accessed June 14 2009."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.29.11.1357","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.29.11.1357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:52:30Z","timestamp":1761069150000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.29.11.1357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1592\/phco.29.11.1357"],"URL":"https:\/\/doi.org\/10.1592\/phco.29.11.1357","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}